Showing results (221-230 of 447) with videos related to
Sort By:
Pageof 45
Oncotarget|June 2, 2018
Lung cancer in never smokers from the Princess Margaret Cancer CentreGrzegorz J Korpanty, Suzanne Kamel-Reid, Melania Pintilie, et al.Respiratory Research|January 1, 2015
Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomasEmily Van de Laar, Monica Clifford, Stefan Hasenoeder, et al.Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2022
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft ModelNadeem Moghal, Quan Li, Erin L Stewart, et al.Oncotarget|March 7, 2018
Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genesTomas Tokar, Chiara Pastrello, Varune R Ramnarine, et al.Translational Lung Cancer Research|March 15, 2021
Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patientsAndrea S Fung, Maryam Karimi, Stefan Michiels, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerDavid M Hwang, Tahani Albaqer, Rex C Santiago, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancerMing-Sound Tsao, Sarit Aviel-Ronen, Keyue Ding, et al.Clinical Lung Cancer|October 31, 2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortiumScott A Laurie, Glenwood D Goss, Frances A Shepherd, et al.The Journal of Thoracic and Cardiovascular Surgery|December 24, 2019
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesotheliomaMarc de Perrot, Licun Wu, Michael Cabanero, et al.Pageof 45